Janagliflozin Treat T2DM Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 442 participants.

Also called NCT03811548

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 442 participants (planned count) (from the registry)
Sponsor
Sihuan Pharmaceutical Holdings Group Ltd. (from the registry)
Registry
  • NCT NCT03811548
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03811548. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-23 (actual); primary completion 2020-06-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Janagliflozin Treat T2DM Monotherapy
Condition
Diabetes Type 2
Intervention (Drug)
Janagliflozin 25mg
Intervention (Drug)
Janagliflozin 50mg
Intervention (Drug)
Placebo/Janagliflozin
Lead sponsor
Sihuan Pharmaceutical Holdings Group Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03811548
Content hash
7646b3f2417dfc092e5bc992f66a3b7b54af1194397b60f584c8dfa84e8fff73